Managed Account Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Managed Account Advisors’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$6.43M	Buy	644,079 +13,129	+2%	+$141K	0.01%	1299
2015 Q1	$8.03M	Buy	630,950 +57,132	+10%	+$734K	0.01%	1188
2014 Q4	$8.12M	Buy	573,818 +666	+0.1%	+$10.3K	0.01%	1154
2014 Q3	$7.88M	Buy	573,152 +135,747	+31%	+$2.08M	0.01%	1140
2014 Q2	$6.73M	Buy	437,405 +25,225	+6%	+$358K	0.01%	1218
2014 Q1	$7.02M	Buy	412,180 +184,365	+81%	+$2.78M	0.01%	1148
2013 Q4	$2.95M	Buy	227,815 +217,099	+2,026%	+$2.59M	﹤0.01%	1554
2013 Q3	$108K	Buy	10,716 +5,274	+97%	+$46.9K	﹤0.01%	2216
2013 Q2	$41K	Buy	+5,442	New	+$42.5K	﹤0.01%	2300

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Managed Account Advisors's KERX Position: Q2 2015 in Review

Managed Account Advisors increased its Keryx Biopharmaceuticals Inc (KERX) stake by 2.1% in Q2 2015, buying an estimated $141K and bringing the position to 644,079 shares worth $6.43M. The position accounts for 0.01% of the portfolio, ranked #1299.

Managed Account Advisors first reported a position in KERX in Q2 2013 and has held it in 9 quarters since. The position peaked at $8.12M in Q4 2014. 153 funds tracked by Wall St. Rank hold KERX as of Q2 2015.

Managed Account Advisors held 644,079 shares of Keryx Biopharmaceuticals Inc worth $6.43M as of Q2 2015.
Managed Account Advisors bought 13,129 Keryx Biopharmaceuticals Inc shares in Q2 2015, an estimated $141K.
Keryx Biopharmaceuticals Inc made up 0.01% of Managed Account Advisors's portfolio in Q2 2015, its #1299 holding.
Managed Account Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and has held it in 9 quarters since.
Managed Account Advisors's Keryx Biopharmaceuticals Inc position peaked at $8.12M in Q4 2014.
153 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.